MARKET NEWS

 

NovaQuest Private Equity Announces Investment In Bend Bioscience to Broaden CoreRx Offering
Servier & OSE Immunotherapeutics Announce Completion of Patient Enrollment in the Phase 2a Clinical Trial of OSE-127/S95011 in Primary Sjögren’s Syndrome
APEIRON Respiratory Therapies Announces Positive Results From Phase I Trial of Inhaled APN01
Inozyme Pharma Announces First Self-Administration of INZ-701 in Ongoing ENPP1 Deficiency Phase 1/2 Clinical Trial
Rhythm Pharmaceuticals Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity 
Processa Successfully Identifies Next-Generation Capecitabine Dosage Regimens for Phase 2B Trial

  FEATURED EDITORIAL

  COMPANY PROFILE

Product realization has never been more complex. Phillips-Medisize supports today’s specialization, regulation, and digitization for fast, efficient product launch on a global scale. For over 60 years, Phillips-Medisize has helped companies develop and manufacture innovative products that help people live healthier and more productive lives. Our integrated end-to-end portfolio of design, development, and manufacturing solutions is built on a solid foundation of specialized capabilities. Click here for more.

  EXCLUSIVE ONLINE CONTENT

 

Exelixis & Catalent Enter New License Agreement for Three Antibody-Drug Conjugate Programs With the Potential to Accelerate Exelixis’ Biologics Pipeline

Exelixis & Catalent Enter New License Agreement for Three Antibody-Drug Conjugate Programs With the Potential to Accelerate Exelixis’ Biologics Pipeline

Exelixis, Inc. and Catalent, Inc. recently announced a new license agreement under which Catalent’s Redwood Bioscience subsidiary will grant Exelixis an exclusive license to three target programs with….

TFF Pharmaceuticals Announces Collaboration With Aptar Pharma to Explore & Develop Intranasal Delivery of Dry Powder Vaccines & Dry Powder Therapeutics

TFF Pharmaceuticals Announces Collaboration With Aptar Pharma to Explore & Develop Intranasal Delivery of Dry Powder Vaccines & Dry Powder Therapeutics

TFF Pharmaceuticals, Inc. recently announced a collaboration with Aptar Pharma aimed at developing and testing the administration of dry powder vaccines utilizing….

Jounce Therapeutics Earns Clinical Milestone Payment Under Exclusive License Agreement With Gilead Sciences

Jounce Therapeutics Earns Clinical Milestone Payment Under Exclusive License Agreement With Gilead Sciences

Jounce Therapeutics, Inc. recently announced earning a $15-million clinical milestone payment from Gilead Sciences, Inc. under the exclusive license agreement for….

Acumen Publishes Phase 1 Trial Design & Clinical Development Plan for an Anti-Amyloid Beta Oligomer Antibody for Alzheimer’s Disease

Acumen Publishes Phase 1 Trial Design & Clinical Development Plan for an Anti-Amyloid Beta Oligomer Antibody for Alzheimer’s Disease

Acumen Pharmaceuticals, Inc. recently announced it published its development rationale and clinical development plan for ACU193, the first clinical-stage monoclonal antibody that selectively targets toxic soluble….

  WHITEPAPERS & WEBINARS


 

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

Lonza has applied it’s 35 years of CMC experience in Biologics to develop an end-to-end comprehensive DS/DP DNA to IND strategy in 13 months. This presentation….

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.

  WHITEPAPERS & WEBINARS

WHITEPAPER WORKSHOP - Soft Mist Inhalers

WHITEPAPER WORKSHOP - Soft Mist Inhalers

Soft mist inhalers (SMIs) are a versatile technology suitable for the delivery of both small and complex large molecules, optimising lung deposition whilst minimising oropharyngeal deposition.

The Resyca® SMI is a joint venture between Recipharm and Medspray that harnesses …

WHITEPAPER - Accelerated API Manufacturing by Combining Early-Stage and Late-Stage Process Development

WHITEPAPER - Accelerated API Manufacturing by Combining Early-Stage and Late-Stage Process Development

Manufacturing Phase 1 clinical material in as little as 12–16 months

Traditionally, early-stage and late-stage process development have been done separately, with early-stage mostly focused on material production and late-stage on process intensification. As more molecules in development fall under …

WHITEPAPER - Key Considerations in Oral Delivery of Peptides – Factors to Consider While Evaluating Oral Administration

WHITEPAPER - Key Considerations in Oral Delivery of Peptides – Factors to Consider While Evaluating Oral Administration

Peptide therapeutics are a hot topic in pharmaceutical R&D. While most peptides are administered parenterally, oral delivery of peptide therapeutics offers several advantages. Enteris BioPharma’s latest whitepaper outlines the key parameters that drug developers should considering while evaluating oral delivery …

WHITEPAPER - Launching a Drug-Device Combination: 5 Key Factors to Focus On

WHITEPAPER - Launching a Drug-Device Combination: 5 Key Factors to Focus On

In today’s fast-growing biopharma market, injectable medications have become a powerful driver of growth and innovation. Within that sector, industry leaders are increasingly focused on one key area: integrating a drug product and a delivery device. As the market expands …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

November 16 – Analytical Instrumentation
November 30 – Formulation Development